Automate Your Wheel Strategy on RGLS
With Tiblio's Option Bot, you can configure your own wheel strategy including RGLS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RGLS
- Rev/Share 0.0
- Book/Share 1.0431
- PB 7.5543
- Debt/Equity 0.0203
- CurrentRatio 16.3052
- ROIC -0.7349
- MktCap 545564708.0
- FreeCF/Share -0.6556
- PFCF -12.5744
- PE -10.9727
- Debt/Assets 0.0187
- DivYield 0
- ROE -0.5753
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | RGLS | Wells Fargo | Equal Weight | Overweight | $3 | $6 | March 27, 2025 |
News
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Regulus Therapeutics Inc. - RGLS
Published: April 30, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , April 30, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Regulus Therapeutics Inc. (NASDAQ: RGLS ), relating to the proposed merger with Novartis AG.
Read More
Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million
Published: April 30, 2025 by: Benzinga
Sentiment: Positive
Novartis AG NVS agreed to acquire Regulus Therapeutics Inc. RGLS on Wednesday for an initial payment of $7.00 per share in cash or $0.8 billion.
Read More
RGLS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Regulus Therapeutics Inc. Is Fair to Shareholders
Published: April 30, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Regulus Therapeutics Inc. (NASDAQ: RGLS) to Novartis AG in cash is fair to Regulus shareholders. Under the terms of the proposed transaction, Regulus shareholders will receive $7.00 per share in cash and a contingent value right providing for payment of $7.00 per share, contingent upon the achievement of a milestone with respect to regulatory approval of Regulus' lead product candidate.
Read More
Shareholder Alert: The Ademi Firm Investigates Whether Regulus Therapeutics Inc. Is Obtaining a Fair Price for Its Public Shareholders
Published: April 30, 2025 by: Business Wire
Sentiment: Neutral
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Regulus (Nasdaq: RGLS) for possible breaches of fiduciary duty and other violations of law in its transaction with Novartis. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, shareholders of Regulus will receive only $7.00 per share in cash at closing, or $0.8 billion. In addition.
Read More
Novartis to buy Regulus Therapeutics for up to $1.7 billion
Published: April 30, 2025 by: Reuters
Sentiment: Positive
Swiss drugmaker Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion to gain access to its experimental kidney disease drug, the California-based drug developer said on Wednesday.
Read More
Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
Basel, April 30, 2025 – Novartis today announced that it has entered into an agreement to acquire Regulus Therapeutics, a San Diego-based, publicly traded (Nasdaq: RGLS) clinical-stage biopharmaceutical company focused on developing microRNA therapeutics. Regulus' lead asset, farabursen, is a potential first-in-class, next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD). The agreed deal is fully in line with the therapeutic area focus of Novartis and leverages our strength and expertise in renal disease.
Read More
Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG
Published: April 30, 2025 by: PRNewsWire
Sentiment: Neutral
Novartis to acquire Regulus for $7.00 per share in cash, with potential to receive an additional $7.00 per share in cash through a contingent value right, for a total equity value of up to approximately $1.7 billion Transaction is expected to be completed in the second half of 2025, subject to customary closing conditions SAN DIEGO , April 30, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it has entered into an agreement and plan of merger with Novartis …
Read More
Should You Buy Regulus (RGLS) After Golden Cross?
Published: April 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Regulus Therapeutics Inc. (RGLS) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, RGLS's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
Read More
Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: March 27, 2025 by: PRNewsWire
Sentiment: Neutral
Positive Topline Data from the Fourth Cohort of Patients Consistent demonstration of polycystin (PC) biomarker impact confirming 300 mg fixed dose selection to achieve optimal kidney exposure Patients receiving 300 mg farabursen demonstrated a mean halting of height-adjusted total kidney volume (htTKV) growth over 4 months Exploratory analysis of patients from high-dose cohorts demonstrates statistical significance in htTKV change compared to a large cohort of historical placebo-treated patients, which meaningfully derisks the 12-month htTKV endpoint in the planned Phase 3 trial Company on track for initiation of Phase 3 single pivotal trial in third quarter 2025 SAN DIEGO , March …
Read More
4 Best Stocks To Buy Under $5
Published: March 20, 2025 by: 24/7 Wall Street
Sentiment: Positive
If you're one of the over 4 Million Americans set to retire this year, you may want to pay attention.
Read More
What Makes Regulus (RGLS) a New Buy Stock
Published: March 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Regulus (RGLS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
About Regulus Therapeutics Inc. (RGLS)
- IPO Date 2012-10-09
- Website https://www.regulusrx.com
- Industry Biotechnology
- CEO Mr. Joseph P. Hagan M.B.A.
- Employees 34